Improvement in disease activity states at 3 months
| MDA (baseline) → LDA (3 months) | MDA (baseline) →REM (3 months) | HDA (baseline) → MDA (3 months) | HDA (baseline) → LDA (3 months) | HDA (baseline) → REM (3 months) | ||
|---|---|---|---|---|---|---|
| Simplified Disease Activity Index (SDAI) | N=1654* | 95 | 38 | 933 | 444 | 144 |
| Relative change, 3 months | 65.2 (13.1) | 90.5 (4.2) | 57.1 (13.9) | 81.1 (7.2) | 95.3 (2.5) | |
| Absolute change, 3 months | 13.9 (4.1) | 19.5 (3.3) | 26.4 (11.8) | 33.4 (11.4) | 39.7(10.5) | |
| % with LDA (incl. REM), 6 months | 77.9% (n=74) | 89.5% (n=34) | 36% (n=336) | 76.4% (n=339) | 93.8% (n=135) | |
| % with REM, 6 months | 22.1% (n=21) | 60.5% (n=23) | 4.5% (n=42) | 21.4% (n=95) | 63.9% (n=92) | |
| Clinical Disease Activity Index (CDAI) | N=1534* | 59 | 25 | 820 | 480 | 150 |
| Relative change, 3 months | 64.9 (13.4) | 90.8 (4.2) | 58.2 (13.6) | 81.2 (7.9) | 96.2 (2.7) | |
| Absolute change, 3 months | 11.6 (3.5) | 16.6 (2.0) | 24.3 (11.2) | 30.5 (11.0) | 35.9 (10.4) | |
| % with LDA (incl. REM), 6 months | 78% (n=46) | 88% (n=22) | 37.2% (n=305) | 75.6% (n=363) | 94% (n=141) | |
| % with REM, 6 months | 22% (n=13) | 60% (n=15) | 5.2% (n=43) | 22.5% (n=108) | 66.7% (n=100) | |
| Disease Activity Score 28-CRP (DAS28-CRP) | N=1740* | 96 | 133 | 1035 | 223 | 253 |
| Relative change, 3 months | 35.6 (7.6) | 54.6 (9.5) | 32.6 (10.3) | 51.8 (5.9) | 65.8 (7.5) | |
| Absolute change, 3 months | 1.6 (0.5) | 2.5 (0.6) | 2.1 (0.8) | 3.2 (0.7) | 4.0 (0.8) | |
| % with LDA (incl. REM), 6 months | 75% (n=72) | 90.2% (n=120) | 31.4% (n=325) | 61.4% (n=137) | 85% (n=215) | |
| % with REM, 6 months | 46.9% (n=45) | 72.9% (n=97) | 13.3% (n=138) | 34.5% (n=77) | 68.4% (n=173) | |
| Disease Activity Score 28-ESR (DAS28-ESR) | N=796* | 26 | 31 | 522 | 99 | 118 |
| Relative change, 3 months | 31.2 (9.8) | 54.2 (9.4) | 35.9 (10.7) | 53.9 (6.1) | 68.1 (8.1) | |
| Absolute change, 3 months | 1.4 (0.6) | 2.4 (0.5) | 2.5 (0.9) | 3.5 (0.8) | 4.4 (1.0) | |
| % with LDA (incl. REM), 6 months | 57.7% (n=15) | 87.1% (n=27) | 27.4% (n=143) | 68.7% (n=68) | 86.4% (n=102) | |
| % with REM, 6 months | 34.6% (n=9) | 71% (n=22) | 13.8% (n=72) | 41.4% (n=41) | 66.7% (n=92) |
Associated absolute and relative changes in the scores, and implications regarding achievement of the target at 6 months.
*The following patients were excluded: patients in LDA or REM already at baseline by the respective score; patients staying in the same state at baseline and 3 months; patients worsening their state from baseline to 3 months. DAS28-ESR numbers are smaller due to the lack of ESR measurement in some of the studies.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; REM, remission.